NIH finalizes changes in conflict of interest rules

Wednesday, August 24, 2011 02:12 PM

The National Institutes of Health has finalized rules to reduce financial conflicts of interests among federally funded researchers who also receive payments or stock from drug and medical device companies, according to a report by the Washington Post.

The rules, which will affect more than 40,000 researchers, come after a string of high profile cases in which federally funded researchers failed to disclose millions of dollars from companies with a financial interest in the outcome of their work.

Researchers who receive more than $5,000 in income from drug or device companies must disclose the payments. Universities or other institutions employing the researchers must collect the data and provide for public access to it.

Institutions will not be forced to disclose conflict-of-interest information online. Instead, they may maintain the data offline and provide it only when requested.

This change reduces the administrative burden of the proposed public disclosure rule for institutions employing federally funded researchers, said Sally Rockey, the NIH’s deputy director for extramural research.

Universities also will be required to develop plans to manage the financial conflicts of individual researchers, but the plans do not have to be made public.

Praising the “vast majority of researchers” as ethical and sensitive to conflicts of interest, NIH director Francis S. Collins called the new rules “an insurance plan against potential trouble downstream.” Collins added that the rules will ensure that government-funded researchers can continue working with private companies.

“We depend critically on those [relationships] for advances in biomedical research, but we do want to make sure. that the highest standards of transparency and integrity are maintained,” Collins said.

This announcement completes the first updating of the conflict-of-interest rules since 1995. As before, violations may be punished by suspension or termination of research funding.

“They’re playing hide the ball on this,” said Paul Thacker, an investigator with the nonprofit Project on Government Oversight. He said all conflict-of-interest information should be published online. “The take-home message is that these are half steps. [NIH] could have taken steps that ensured the trust of American taxpayers who are funding this research, but they chose not to take those steps.”

The issue of corporate payments to medical researchers has exploded in recent years. In an influential 2009 report, the Institute of Medicine said such conflicts “threaten the integrity of scientific investigations.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

May 20

IRB consolidation trend continues, as private equity firm Audax buys majority stake in Chesapeake

Quintiles, Merck Serono ink exclusive partnership

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

INC Research, PPD, inVentiv named top CROs
Yet most CROs slipping in ability to manage site relationships

R&D cuts by sponsors spur more collaboration, innovation
New strategies share pipeline activity costs

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

20 innovators changing the face of the clinical trials industry
The CenterWatch Monthly honors individuals, teams and companies for their forward-thinking ideas and their ability to implement them.

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs